DermTech, Inc. , a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern.
- Trust 2 Study confirms negative predictive value of 99.7% for the foundational gene expression assay
- Optional TERT promoter mutation testing does not significantly alter sensitivity, NPV or.
DermTech, Inc. , a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced agreements with Highmark Inc. . The contracts, which are in addition to a.